Latest Capital Raises News

North Stawell Minerals has launched its 2025 diamond drilling program targeting significant gold mineralisation at the Wildwood and Darlington prospects in Victoria, backed by a recent $1.3 million capital raise.

Green Critical Minerals Limited (ASX: GCM) has temporarily paused trading of its securities, signaling an impending announcement that investors should watch closely.

Orthocell Limited has reported a third consecutive quarter of record revenue, driven by strong sales growth and strategic market expansions, including a key US FDA submission for its nerve repair product Remplir™.

Sipa Resources has inked agreements to acquire four advanced gold projects in South Australia and Western Australia, positioning itself for a significant exploration boost. The $2.2 million deal, coupled with a $1.75 million capital raise, signals a strategic pivot towards expanding its resource base.

GreenTech Metals has restarted its stage 2 diamond core drilling at the Whundo Cu-Zn project in West Pilbara, backed by a completed $2.3 million placement to fund exploration and resource expansion efforts.

Anatara Lifesciences has successfully completed recruitment for the second stage of its pivotal GaRP-IBS clinical trial, with headline results expected in Q1 2025. The company also launched a new anti-obesity project and strengthened its cash position through recent capital raises.

Arafura Rare Earths has locked in a A$200 million convertible note investment from the National Reconstruction Fund Corporation, marking a pivotal step toward developing Australia's first ore-to-oxide rare earths processing operation at Nolans.

Megado Minerals has secured an agreement to acquire an 80% stake in a significant copper project in Spain and entered a strategic exploration deal for rare earths in the US, positioning itself at the forefront of critical minerals supply.

Nex Metals Explorations has repriced and partially completed its capital raise, securing $1.06 million at a reduced share price to fund development and exploration activities.

Vonex Limited has vested performance rights for its CEO and directors following MaxoTel’s acquisition of majority control, with shares set to be sold on-market. The company reports a mixed 1H FY25 financial performance and is exploring options to repay a $23 million debt facility, including a potential capital raise.

Centrex Limited has initiated a $10.4 million entitlement offer to fund essential plant upgrades and strengthen working capital, following a strategic logistics debt restructuring. The raise is pivotal for advancing the Ardmore phosphate project and maintaining financial viability.

Mesoblast has raised A$260 million through a global private placement to fund the US commercial launch of its FDA-approved cell therapy Ryoncil® and accelerate clinical development in chronic low back pain.